XML 27 R16.htm IDEA: XBRL DOCUMENT v3.25.2
SEGMENTS
 6 Months Ended
Jun. 30, 2025
SEGMENTS [Abstract]  
SEGMENTS
10.
SEGMENTS
 
The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The Company’s ADMA BioManufacturing operating segment reflects the Company’s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL. The Plasma Collection Centers operating segment consists of ten plasma collection facilities located throughout the United States, all of which are operational, collecting plasma and currently hold FDA licenses. The Company defines its operating segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (“CODM”) to analyze performance and allocate resources. While not considered an operating segment, the Corporate information included in the tables below consists of certain unallocated general and administrative overhead expenses and interest expense on the Company’s senior debt (see Note 6). The Company’s CODM is its President and Chief Executive Officer. For the Company’s two operating segments, the CODM uses income/loss before taxes as the measure of segment profit to determine the allocation of resources for each segment. Summarized financial information concerning reportable segments is shown in the following tables:
            
Three Months Ended June 30, 2025
(in thousands)
  
ADMA
BioManufacturing
    
Plasma Collection
Centers
    
Total
 
Revenues
 $121,948   $   -    $121,948 
               
Cost of product revenue
  54,757      -     54,757 
               
Research and development
  1,031      -     1,031 
               
Plasma center operating expenses
    -     1,152    1,152 
               
Selling, marketing and distribution
  5,868      -     5,868 
               
Amortization of intangible assets
  32      -     32 
               
General and administrative expense
  14,941      -     14,941 
               
Other expense, net
  (108)      -     (108) 
               
Income (loss) before taxes
  45,211    (1,152)    44,059 
               
Expenditures for additions to long-lived assets
  2,034    (7)    2,027 
Total assets
  368,229    29,161    397,390 
               
Reconciliation of revenues:
              
Segment revenue
           $121,948 
License revenue
            36 
Consolidated revenues
           $121,984 
               
Reconciliation of selling, general and administrative expense:
              
Segment selling, marketing and distribution expense
           $5,868 
Segment general and administrative expense
            14,941 
Corporate general and administrative expense (a)
            1,405 
Consolidated selling, general and administrative expense
           $22,214 
               
Reconciliation of income before taxes:
              
Segment income before taxes
           $44,059 
License revenue
           36 
Unallocated interest expense, primarily related to interest on senior debt (see Note 6)
            (1,834) 
Unallocated interest income
            400 
Loss on extinguishment of debt
            (1,159) 
Corporate general and administrative expense (a)
            (1,405) 
Consolidated income before taxes
           $40,097 
               
Reconciliation of total assets:
              
Total segment assets
           $397,390 
Corporate (b)
            160,990 
Consolidated total assets
           $558,380 
 
(a)
-
Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.
     
(b)
-
Primarily consists of cash and deferred tax assets.
               
Six Months Ended June 30, 2025
(in thousands)
 
ADMA
BioManufacturing
    
Plasma Collection
Centers
    
Total
 
Revenues
$235,665   $1,050   $236,715 
               
Cost of product revenue
 107,814    649    108,463 
               
Research and development
 1,858     -     1,858 
               
Plasma center operating expenses
  -     2,438    2,438 
               
Selling, marketing and distribution
 11,911     -     11,911 
               
Amortization of intangible assets
 57     -     57 
               
General and administrative expense
 30,024     -     30,024 
               
Other expense, net
 (172)     -     (172) 
               
Income (loss) before taxes
 83,829    (2,037)    81,792 
               
Expenditures for additions to long-lived assets
 6,733    14    6,747 
Total assets
 368,229    29,161    397,390 
               
Reconciliation of revenues:
             
Segment revenue
          $236,715 
License revenue
           71 
Consolidated revenues
          $236,786 
               
Reconciliation of selling, general and administrative expense:
             
Segment selling, marketing and distribution expense
          $11,911 
Segment general and administrative expense
           30,024 
Corporate general and administrative expense (a)
           4,357 
Consolidated selling, general and administrative expense
          $46,292 
               
Reconciliation of income (loss) before taxes:
             
Segment income before taxes
          $81,792 
License revenue
           71 
Unallocated interest expense, primarily related to interest on senior debt (see Note 6)
           (3,809) 
Unallocated interest income
           1,008 
Loss on extinguishment of debt
           (1,159) 
Corporate general and administrative expense (a)
           (4,357) 
Consolidated income before taxes
          $73,546 
               
Reconciliation of total assets:
             
Total segment assets
          $397,390 
Corporate (b)
           160,990 
Consolidated total assets
          $558,380 
 
   
(a)
-
Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.
 
 
 
(b)
-
Primarily consists of cash and deferred tax assets.
               
Three Months Ended June 30, 2024
(in thousands)
  ADMA BioManufacturing      Plasma Collection
Centers 		     Total  
Revenues
$106,183   $972   $107,155 
               
Cost of product revenue
 48,471    1,267    49,738 
               
Research and development
 560     -     560 
               
Plasma center operating expenses
  -     942    942 
               
Selling, marketing and distribution
 4,504     -     4,504 
               
Amortization of intangible assets
 142     -     142 
               
General and administrative expense
 5,791     -     5,791 
               
Other expense, net
 (13)    (3)    (16) 
               
Income (loss) before taxes
 46,702    (1,240)    45,462 
               
Expenditures for additions to long-lived assets
 1,210    58    1,268 
Total assets
 258,094    33,607    291,701 
               
Reconciliation of revenues:
             
Segment revenue
          $107,155 
License revenue
           36 
Consolidated revenues
          $107,191 
               
Reconciliation of selling, general and administrative expense:
             
Segment selling, marketing and distribution expense
          $4,504 
Segment general and administrative expense
           5,791 
Corporate general and administrative expense (a)
           6,313 
Consolidated selling, general and administrative expense
          $16,608 
               
Reconciliation of income (loss) before taxes:
             
Segment income before taxes
          $45,462 
License revenue
           36 
Unallocated interest expense, primarily related to interest on senior debt (see Note 6)
           (3,783) 
Unallocated interest income
           449 
Corporate general and administrative expense (a)
           (6,313) 
Consolidated income before taxes
          $35,851 
               
Reconciliation of total assets:
             
Total segment assets
          $291,701 
Corporate (b)
           84,698 
Consolidated total assets
          $376,399 
 
   
(a)
-
Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.
 
 
 
(b)
-
Primarily consists of cash and deferred tax assets.
               
Six Months Ended June 30, 2024
(in thousands)
  ADMA BioManufacturing      Plasma Collection
Centers 		     Total  
Revenues
$186,297   $2,698   $188,995 
               
Cost of product revenue
 89,462    3,043    92,505 
               
Research and development
 1,010     -     1,010 
               
Plasma center operating expenses
  -     1,947    1,947 
               
Selling, marketing and distribution
 8,935     -     8,935 
               
Amortization of intangible assets
 335     -     335 
               
General and administrative expense
 11,140     -     11,140 
               
Other expense, net
 (47)    (4)    (51) 
               
Income (loss) before taxes
 75,368    (2,296)    73,072 
               
Expenditures for additions to long-lived assets
 4,338    75    4,413 
Total assets
 258,094    33,607    291,701 
               
Reconciliation of revenues:
             
Segment revenue
          $188,995 
License revenue
           71 
Consolidated revenues
          $189,066 
               
Reconciliation of selling, general and administrative expense:
             
Segment selling, marketing and distribution expense
          $8,935 
Segment general and administrative expense
           11,140 
Corporate general and administrative expense (a)
           12,172 
Consolidated selling, general and administrative expense
          $32,247 
               
Reconciliation of income (loss) before taxes:
             
Segment income before taxes
          $73,072 
License revenue
           71 
Unallocated interest expense, primarily related to interest on senior debt (see Note 6)
           (7,552) 
Unallocated interest income
           833 
Corporate general and administrative expense (a)
           (12,172) 
Consolidated income before taxes
          $54,252 
               
Reconciliation of total assets:
             
Total segment assets
          $291,701 
Corporate (b)
           84,698 
Consolidated total assets
          $376,399 
 
   
(a)
-
Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company's operating segments.
 
 
 
(b)
-
Primarily consists of cash and deferred tax assets.
Net revenues according to geographic area, based on the location of where the product is shipped, were as follows:
 
                     
  Three Months Ended June 30,   Six Months Ended June 30,
(in thousands)
  2025      2024       2025      2024  
United States
$121,984   $102,726    $232,714   $180,717 
International
  -     4,465     4,072    8,349 
Total revenues
$121,984   $107,191    $236,786   $189,066